Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Pediatric Enhanced Surveillance Study (PESS)

4 décembre 2015 mis à jour par: Elaine J. Abrams, MD, Columbia University

Enhanced Surveillance and 2 Year Outcomes of Children Enrolled on Antiretroviral Therapy (ART) in Public Health Facilities in the Eastern Cape Province, South Africa

The Pediatric Enhanced Surveillance Study is a three part study of HIV-infected infants and children in South Africa to examine, clinical, immunologic, virologic, metabolic, psychosocial and behavioral outcomes. This study has two parts: (1) comprehensive de-identiﬁed records review of all HIV-infected children enrolled in at the pediatric Wellness and ART clinics at the ﬁve study sites; and (2) a prospective cohort surveillance study with active consented enrollment with 12-24 months of follow-up. As part of the prospective cohort, the study will aim to collect outcomes on children lost to follow-up, including causes of death through review of death certiﬁcates in the clinical chart and through verbal autopsy reports. The study will provide insights into overall outcomes for the larger pediatric patient populations in the province and South Africa. This work is designed in collaboration with the provincial health authorities of the Eastern Cape Department of Health (EC), The International Center for acquired immune deficiency syndrome (AIDS) Care and Treatment Programs (ICAP) South Africa and Center of Disease Control (CDC)-South Africa in support of the South African National ART Program for Children and aims to collect and analyze accurate, relevant and useful information that will be available on children seen at facilities. For the prospective cohort study, we will aim to enroll 400 children newly initiated on ART at 5 health facilities in the Eastern Cape of South Africa who will be actively followed for up to 24 months.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

South Africa is one of the countries hardest hit by the HIV/AIDS epidemic. There are more than 5 million people living with HIV in South Africa, including 280,000 children under the age of 15. Most HIV positive children acquire infection through mother-to-child transmission; in South Africa 29.3% of pregnant women attending antenatal services are HIV-infected. Furthermore, it is estimated that HIV is the cause of 35% of all deaths in children under five in South Africa. The South African government began a national rollout of HIV treatment for adults and children in 2003. As of 2007, an estimated 32,060 children under the age of 15 were receiving antiretroviral therapy (roughly 30% of those in need). There is an urgent need to obtain more comprehensive, in-depth, profiles of children enrolled in HIV care with a focus on documenting outcomes, particularly timing and causes of death, reasons for loss to follow-up, timing and frequency of treatment failure, adverse events, metabolic complications and psychosocial aspects of HIV disease.

Type d'étude

Observationnel

Inscription (Réel)

396

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Afrique du Sud
- Amathole
  - East London, Amathole, Afrique du Sud
    - Cecilia Makiwane Hospital
  - East London, Amathole, Afrique du Sud
    - Frere Hospital
- Nelson Mandela Bay
  - Port Elizabeth, Nelson Mandela Bay, Afrique du Sud
    - Dora Ngiza Hospital
  - Port Elizabeth, Nelson Mandela Bay, Afrique du Sud
    - Kwazakhele Community Health Center
  - Port Elizabeth, Nelson Mandela Bay, Afrique du Sud
    - Motherwell Community Health Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 mois à 12 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Human immunodeficiency virus (HIV)-infected children accessing HIV care and treatment services in the Eastern Cape of South Africa are the population of interest for the overall study.

Records review: All children with a record of care at the study facilities in the Wellness or antiretroviral (ART) clinic will form the study population.
Prospective cohort: ART-naïve children receiving care at participating sites who have reached eligibility for ART and consent to participate will form the study population. The sample for the study will be a subset of all children enrolled and receiving care at these public health care facilities.

La description

Inclusion Criteria:

The child is eligible for antiretroviral therapy (ART) initiation based on the South African Pediatric HIV guidelines.
The child has documentation of being HIV-infected by a positive HIV-Deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), detectable HIV ribonucleic acid (RNA) viral load or a positive HIV antibody test (>18 months of age).
The child has no prior history of treatment with ART other than prophylaxis for preventing mother to child transmission (PMTCT) (may be initiating ART on day of enrollment in study).
The child is between 1 month and 12 years of age.
The parent or legal guardian provides written consent for participation.
The child provides assent for participation based on South African guidance for minors.

Exclusion Criteria:

Any subject not meeting all of the above inclusion criteria will not be eligible for the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte Groupe / Cohorte Groupe ou sous-groupe de participants à une étude observationnelle dont les résultats biomédicaux ou sanitaires sont évalués.
Prospective Cohort The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will: review routinely collected information; conduct questionnaires with caregiver and child; conduct additional assessments of child; contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking.

Groupe / Cohorte

Prospective Cohort

The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:

review routinely collected information;
conduct questionnaires with caregiver and child;
conduct additional assessments of child;
contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and
conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats	Description de la mesure	Délai
Proportion of children alive and in care at 12 and 24 months after treatment initiation Délai: Up to 24 months	We will measure the proportion of children alive and in care at 12 and 24 months after treatment initiation amount prospective cohort participants through routine clinical and study visits.	Up to 24 months

Mesures de résultats secondaires

Mesure des résultats	Description de la mesure	Délai
Proportion of the children enrolled in human immunodeficiency virus (HIV) care and treatment services Délai: Up to 24 months	We will describe the proportion of the children enrolled in HIV care and treatment services at the study facilities who start treatment and are retained in care for 6, 12, 24, 36 and 48 months by reviewing clinical records at each facility.	Up to 24 months
Proportion of children lost to follow-up Délai: Up to 24 months	We will describe the proportion of children lost to follow-up after enrollment in care and in those starting treatment by reviewing clinical records of study participants.	Up to 24 months
Proportion of children with documented deaths Délai: Up to 24 months	We will describe proportion of children with documented deaths and causes of deaths and time to death (from enrollment) by reviewing clinical records of participants.	Up to 24 months
Proportion of children who are virologically suppressed Délai: Up to 24 months	We will measure the proportion of children who are virologically suppressed (< 400 copies/mL, per South African National Guidelines) at 12 and 24* months after treatment initiation in the prospective cohort through routine clinical and study visits.	Up to 24 months
Proportion of children on antiretroviral therapy (ART) with diminished CD4 (cluster of differentiation 4) counts Délai: Up to 24 months	We will measure the proportion of children, aged 2 to 5 years, on ART with CD4% <10% at 12, 24* months after treatment initiation and children older than 5 years on ART with CD4 count of < 100 at 12, 24 months after treatment initiation. These outcomes will be measured in participants of the prospective cohort who will give additional blood samples during routine clinical care.	Up to 24 months
Proportion of children on antiretroviral therapy (ART) progressing to WHO Stage 4 disease Délai: Up to 24 months	We will measure the proportion of children on ART progressing to WHO Stage 4 disease at 12 and 24 months after treatment initiation in the prospective cohort.	Up to 24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Columbia University

Collaborateurs

Centers for Disease Control and Prevention

Les enquêteurs

Chercheur principal: Elaine Abrams, MD, ICAP-NY, Columbia University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 avril 2012

Achèvement primaire (Réel)

1 octobre 2015

Achèvement de l'étude (Réel)

1 octobre 2015

Dates d'inscription aux études

Première soumission

13 janvier 2014

Première soumission répondant aux critères de contrôle qualité

21 janvier 2014

Première publication (Estimation)

23 janvier 2014

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

7 décembre 2015

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 décembre 2015

Dernière vérification

1 décembre 2015

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

AAAI1736
U2GPS001537 (Subvention/contrat des NIH des États-Unis)
U262PS223540 (Autre subvention/numéro de financement: MCAP)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .